Phesi urges smarter use of oncology trial data as ASCO 2025 nears
US analytics specialist Phesi has called for a major rethink in how oncology trials are planned and run, saying clinical development has failed to keep pace with scientific progress.
Ahead of the ASCO 2025 meeting, Phesi released new figures showing vast troves of real-world patient data remain underused by trial sponsors. The firm’s AI-powered Trial Accelerator platform has now amassed 167 million contextualized patient records, with colorectal cancer data alone representing nearly 6 million patients across more than 18,000 cohorts.
That figure tops other major cancers, including breast (4.8 million), lung (3 million), liver (2.3 million), and prostate (2.2 million), according to the company.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
More on this story...
Today's issue
Company Spotlight
More Features in Pharmaceutical
Copyright © The Pharma Letter 2025 | Headless Content Management with Blaze